13 August 2015 -  PHARMAC has announced the approval of an agreement with Actelion Pharmaceuticals Australia Pty Limited to list epoprostenol sodium injection (Veletri) in Part II of Section H (the Hospital Medicines List or HML) of the Pharmaceutical Schedule.

This was the subject of a consultation letter dated 26 June 2015, available on PHARMAC’s website.

For more details, go to: http://www.pharmac.health.nz/news/notification-2015-08-13-epoprostenol-injection/